帕金森伴慢性心力衰竭患者心率变异性的变化特点及其与心功能指标和预后的关系

发布时间：2018-06-03 05:20

  本文选题：帕金森病 + 慢性心力衰竭　； 参考：《广东医学》2017年22期

【摘要】：目的探讨帕金森伴慢性心力衰竭(简称心衰)患者心率变异性(HRV)的变化特点及其与心功能指标及预后的关系。方法以帕金森伴慢性心衰患者46例为观察组,另选取30例同期单纯帕金森病患者为帕金森组,30例同期健康查体者为对照组。检测比较3组入选次日的高频(HF)、低频(LF)和高频、低频比(HF/LF)等HRV指标和左室射血分数(LVEF)。统计观察组随访半年的心血管事件发生率和死亡率,并分析帕金森伴慢性心衰患者HRV与其LVEF、心血管事件发生率和死亡率的关系。结果与帕金森组和对照组比较,观察组的HF、HF/LF和LVEF均降低,LF则升高(P0.05)。与对照组比较,帕金森组HF、HF/LF和LVEF亦均降低,LF则升高(P0.05)。观察组随访半年的心血管事件发生率和死亡率分别为17.39%和13.04%。观察组LVEF≥50%患者的HF和HF/LF均高于LVEF50%患者,LF则低于LVEF50%患者(P0.05)。观察组存活患者的HF和HF/LF均高于死亡患者,LF则低于死亡患者(P0.05)。且观察组无心血管事件患者的HF和HF/LF均高于有心血管事件患者,LF则低于有心血管事件患者(P0.05)。Pearson线性相关分析结果显示,帕金森伴慢性心衰患者HF和HF/LF与其LVEF均呈正相关(r=0.882、0.853,P0.05),其LF与其LVEF则呈负相关(r=-0.792,P0.05)。Spearman无条件相关分析结果显示,帕金森伴慢性心衰患者HF和HF/LF与其心血管事件发生率和死亡率均呈负相关(HF:r=-0.812、-0.833;HF/LF:r=-0.825、-0.871,P0.05),其LF与其心血管事件发生率和死亡率则呈正相关(r=0.805、0.816,P0.05)。结论帕金森伴慢性心衰患者HRV降低且与其心功能降低和不良预后密切相关,HRV指标的检测有助于其心功能和预后评估,指导其治疗和预后干预。
[Abstract]:Objective to investigate the changes of heart rate variability (HRV) in patients with Parkinson's disease and chronic heart failure (CHF) and the relationship between HRV and cardiac function and prognosis. Methods 46 cases of Parkinson's disease with chronic heart failure as observation group and another 30 cases of Parkinson's disease as control group were selected as control group. The HRV index and left ventricular ejection fraction (LVEF) were measured and compared in three groups. The incidence and mortality of cardiovascular events and the relationship between HRV and LVEF, incidence of cardiovascular events and mortality in patients with Parkinson's disease and chronic heart failure were analyzed. Results compared with Parkinson's group and control group, both HFF / LF and LVEF in the observation group were decreased and LF was increased (P 0.05). Compared with the control group, HFR / LF and LVEF in PD group were decreased, and LF increased (P 0.05). The incidence and mortality of cardiovascular events in the observation group were 17.39% and 13.04% respectively. In the observation group, HF and HF/LF in patients with LVEF 鈮，

本文编号：1971619